🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

At #ASCO25: A cell-free, DNA-guided strategy in advanced #NSCLC helped personalize first-line treatment—identifying patients who may delay or avoid chemo without compromising outcomes. Presented by Julia Rotow MD Dana-Farber

#ScooperBowl has officially kicked off at Boston City Hall Plaza! Join us now through Thursday, 12-8pm each day, for unlimited ice cream all to benefit Dana-Farber. 🍦🩷 Use code CONES for $4 off each ticket at checkout: jimmyfund.gives/XDay #Boston #BostonEvents

An anti-inflammatory diet may help colon cancer patients live longer, study says. Dana-Farber’s Sara Khosrowjerdi Char, MD and Kimmie Ng, MD, MPH talked with NBC News about their research on diet and #coloncancer presented at #ASCO25: bit.ly/451IZOb

First study of triplet combination of letrozole, abemaciclib, and metformin in any cancer type reported at #ASCO25. Panos Konstantinopoulos, MD, PhD, of Dana-Farber says the results of a phase 2 study in ER+ recurrent #endometrial cancer were encouraging.

Congratulations to Dana-Farber’s Miriam Agyakomah Osei, MD for being selected by ASH to receive the 2025 ASH Hematology Inclusion Pathway (HIP) Fellow Award (under the mentorship of Drs. Lachelle Dawn and Coleman Lindsley). This is part of ASH’s investment in research and

In a recent podcast episode with Blood Cancer Talks, Daniel DeAngelo, MD, PhD, Chief of our Division of Leukemia, discusses the management of systemic mastocytosis, highlighting key studies and ongoing research for treating this condition. Listen here: bit.ly/45cObip

In 2023, the FDA approved belzutifan for certain kidney cancers –– thanks to years of work led by Nobel Prize recipient William G. Kaelin Jr., MD, KaelinLab. Now, Toni Choueiri, MD, director of Dana-Farber Lank Center for Genitourinary Oncology, and team are working to expand its clinical use. bit.ly/3GNeb9D

We’re proud to be recognized by Newsweek as one of America’s Greatest Workplaces in Healthcare 2025! Thank you to our incredible staff who makes Dana-Farber such a special place to work. View the full list here: bit.ly/3SH7cC6

Cold plunges are gaining popularity for their reported benefits, from reducing inflammation to aiding muscle recovery and boosting mood. The positive effects are numerous — but can cold plunges prevent or treat cancer? Learn what the research says: bit.ly/4dAiuRW

ICYMI at #ASCO25: 1L SG + pembro significantly improves PFS compared w/ chemo + pembro in PD-L1–positive triple-negative #breastcancer; combo was associated w/ 35% reduction in risk of disease progression or death: brnw.ch/21wTiLO #ASCODailyNews

In a new Nucleic Acids Res study, Dana-Farber researchers led by छपरा का धुरंधर reveal how foamy virus (FV) targets DNA based on replication timing and chromatin structure. Read more: bit.ly/4kYevRR

Last week, 73 Dana-Farber researchers presented their latest findings at #ASCO25. From groundbreaking data to innovative treatment - here’s a peek at some of the learnings. 🎥 ⬇️

.Shail Maingi, MD, MD, brought her experience in LGBTQ+ inclusive cancer care to India, supporting efforts to better serve LGBTQ+ patients. Read how this global effort is supporting more inclusive care: bit.ly/4dBsI4M

Jacob sands, of Dana-Farber presents promising early-phase trial results for obrixtamig, a novel DLL3-targeting T-cell engager, in patients with large cell neuroendocrine carcinoma of the lung. Watch the full video here: hubs.li/Q03rShqP0

A team of researchers, led by principal investigator and thoracic oncologist Narjust Florez, MD, FASCO, associate director of our Cancer Care Equity Program, launch a first-of-its-kind study to use a novel blood test to identify people who have never used tobacco but are at a high risk of

#BREAKING The FDA has approved pembrolizumab as the first new standard-of-care treatment for patients with resectable locally advanced #HeadandNeck cancer in 20+ years. Approval based on the pivotal KEYNOTE-689 trial led by Ravi Uppaluri, MDPhD of the Dana-Farber Brigham Cancer Center.

Congratulations to Dana-Farber’s Judith Agudo who has been named a 2025 CRI Lloyd J. Old STAR by Cancer Research Institute for her innovative contributions to the field of cancer immunotherapy.

On #WorldBloodDonorDay, we celebrate selfless donors like the friends recently featured as WBZ | CBS News Boston Change Makers who have supported Dana-Farber by donating blood platelets at Kraft Family Blood Donor Center and riding in the Pan-Mass Challenge for an astonishing 15 years. ➡️ bit.ly/4kyO5Xl

Congratulations to Toni Choueiri, MD on being the recipient of a Doctorate Honoris Causa from The Lebanese University recognizing his outstanding achievements in Oncology.

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab, recently approved by the FDA, before, during and after standard-of-care surgery had had improved outcomes, according to a clinical trial led by investigators from